Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgolide is a pharmaceutical-grade injection containing terpene lactones (specifically ginkgolides A, B, and C) derived from *Ginkgo biloba* extract. Developed and manufactured by Chengdu Baiyu Pharmaceutical, it is primarily used as an adjunctive treatment for acute ischemic stroke. The drug functions as a potent antagonist of the platelet-activating factor (PAF) receptor, thereby inhibiting platelet aggregation and reducing the risk of thrombus formation and reocclusion following thrombolysis. Additionally, it exhibits neuroprotective and anti-inflammatory properties by modulating cytokines such as TNF-α and IL-6, protecting the blood-brain barrier, and reducing ischemia-reperfusion injury. It has been evaluated in the Phase 4 GIANT trial by the Second Affiliated Hospital, School of Medicine, Zhejiang University, in combination with intravenous alteplase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ginkgolide.